DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)

Active, not recruiting

Conditions: Melanoma

Interventions: Drug: Ipilimumab

First Posted Date: 2019-12-12

Last Posted Date: 2019-12-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 10

Registration Number: NCT04196452

Locations: 🇺🇸
Local Institution, Princeton, New Jersey, United States

Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

Phase 2

Completed

Conditions: Autoimmune Disorder
Rheumatoid Arthritis
Systemic Lupus Erythematosus
Primary Sjögren's Syndrome

Interventions: Drug: branebrutinib placebo
Drug: branebrutinib
Drug: abatacept

First Posted Date: 2019-12-05

Last Posted Date: 2024-01-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 119

Registration Number: NCT04186871

Locations: 🇺🇸
Local Institution - 0083, Spokane, Washington, United States
🇺🇸
Local Institution - 0024, Encino, California, United States
🇫🇷
Local Institution - 0075, Brest, France

and more 71 locations

A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986322
Drug: famotidine
Other: BMS-986322 Placebo

First Posted Date: 2019-11-25

Last Posted Date: 2022-05-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 171

Registration Number: NCT04175925

Locations: 🇺🇸
ICON (LPRA) - Lenexa, Lenexa, Kansas, United States

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea

Phase 3

Completed

Conditions: Psoriasis

Interventions: Other: Placebo
Drug: BMS-986165

First Posted Date: 2019-11-18

Last Posted Date: 2023-03-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 220

Registration Number: NCT04167462

Locations: 🇨🇳
Local Institution - 0031, Taipei, Taiwan
🇨🇳
Local Institution - 0012, Jingan, Shanghai, China
🇨🇳
Local Institution - 0014, Beijing, Beijing, China

and more 28 locations

A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab Therapy

Completed

Conditions: Hepatocellular Carcinoma

First Posted Date: 2019-11-13

Last Posted Date: 2019-11-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1426

Registration Number: NCT04161911

Locations: 🇺🇸
Bristol Myers Squibb, CORDS Research, Princeton, New Jersey, United States

A Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of Single and Multiple Doses of BMS-986209 in Healthy Participants

Phase 1

Completed

Conditions: Health Participants

Interventions: Drug: BMS-986209
Other: BMS-986209 Placebo
Drug: Itraconazole
Drug: Diltiazem

First Posted Date: 2019-11-07

Last Posted Date: 2022-01-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 114

Registration Number: NCT04154800

Locations: 🇺🇸
PPD Development, LP, Austin, Texas, United States

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Phase 1

Withdrawn

Conditions: Carcinoma, Non-small Cell Lung Cancer

Interventions: Biological: nivolumab
Biological: docetaxel
Biological: ipilimumab
Drug: lucitanib
Drug: cabozantinib
Biological: ramucirumab

First Posted Date: 2019-11-05

Last Posted Date: 2023-12-19

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT04151563

Locations: 🇷🇴
Local Institution, Timisoara, Romania

A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)

Phase 3

Terminated

Conditions: Urinary Bladder Neoplasms

Interventions: Drug: nivolumab
Other: Placebo
Biological: Bacillus Calmette-Guérin (BCG)

First Posted Date: 2019-11-04

Last Posted Date: 2024-04-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 13

Registration Number: NCT04149574

Locations: 🇦🇺
Local Institution - 0002, Sydney, New South Wales, Australia
🇦🇷
Local Institution - 0088, Capital Federal, Buenos Aires, Argentina
🇯🇵
Local Institution - 0150, Shinjuku-Ku, Tokyo, Japan

and more 78 locations

An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia

Completed

Conditions: Melanoma

Interventions: Drug: nivolumab

First Posted Date: 2019-10-31

Last Posted Date: 2025-01-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 150

Registration Number: NCT04146324

Locations: 🇦🇺
Local Institution, Malvern, Victoria, Australia
🇦🇺
Local Institution - 0006, Woodville South, South Australia, Australia

A Study of Hospital Healthcare Use and Cost in Patients in the Hospital With a Venous Thromboembolism (VTE) Treated With Apixaban or Warfarin in the US

Completed

Conditions: Venous Thromboembolism (VTE)

First Posted Date: 2019-10-28

Last Posted Date: 2019-10-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 28000

Registration Number: NCT04141228

Locations: 🇺🇸
Local Institution, Flemington, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy